• Vaccine Name: Recombinant VEE Replicons expressing MBGV NP
• Target Pathogen: Marburg Virus
• Target Disease: Hemorrhagic fever
• Vaccine Ontology ID: VO_0004126
• Type: Recombinant vector vaccine
• Antigen: Marburg virus (MBGV) nucleoprotein (NP) (Hevey et al., 1998).
• NP from Marburg virus Musoke gene engineering:
  • Type: Recombinant protein preparation
  • Description: The ORF for the glycoproteins were generated by PCR and cloned into GP-lacking VSV vectors (Daddario-DiCaprio et al., 2006).
  • Detailed Gene Information: Click Here.
• Preparation: A gene coding for a protein of interest is cloned in place of the VEE virus structural genes (Hevey et al., 1998).
• Virulence: Without any observed signs of illness, all animals that received VEE replicons expressing MBGV GP, either alone or in combination with MBGV NP, survived challenge with 8000 PFU MBGV(Hevey et al., 1998).

Monkey Response

• Host Strain: cynomolgus
• Vaccination Protocol: Several groups of macaques were tested: a group received VRPs that expressed MBGV NP; a group received VRPs that expressed MBGV GP; a group received a mixture of MBGV GP and MBGV NP VRPs; and a group received VRPs that expressed a control antigen (influenza HA)Anti-MBGV ELISA antibody titers were monitored throughout the experiment
• Persistence: Not noted.
• Immune Response: Animals inoculated with replicons that expressed MBGV proteins demonstrated prechallenge ELISA titers to purified MBGV antigen. Of the GP-vaccinated animals that survived challenge, a few demonstrated a modest boost in ELISA antibody titer (10- to 30-fold) when pre and postchallenge samples were compared. The surviving NP-inoculated macaques had larger boosts in ELISA antibody titers when pre- and
  postchallenge samples were compared. Some animals vaccinated with both GP and NP also demonstrated 100- to 300-fold rise in ELISA titers(Hevey et al., 1998).
• Side Effects: Not noted.
• Challenge Protocol: Monkeys recieved injections that expressed VEE replicons with either MBGV GP or MBGV NPor both(Hevey et al., 1998).
• Efficacy: All animals that received VEE replicons expressing MBGV GP, either alone or in combination with MBGV NP, survived challenge with 8000 PFU MBGV without any observed signs of illness(Hevey et al., 1998).